References

Adeghate, E., 2008. Visfatin: Structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem., 15: 1851-1862.
Direct Link  |  

Alexiadou, K., A. Kokkinos, S. Liatis, D. Perrea, N. Katsilambros and N. Tentolouris, 2012. Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration. Hormones (Athens), 11: 444-450.
Direct Link  |  

Bae, S.K., S.R. Kim, J.G. Kim, J.Y. Kim and T.H. Koo et al., 2006. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett., 580: 4105-4113.
CrossRef  |  

Banks, A.S., N. Kon, C. Knight, M. Matsumoto and R. Gutierrez-Juarez et al., 2008. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab., 8: 333-341.
CrossRef  |  Direct Link  |  

Bowles, D.K. and M.H. Laughlin, 2011. Mechanism of beneficial effects of physical activity on atherosclerosis and coronary heart disease. J. Applied Physiol., 111: 308-310.
CrossRef  |  Direct Link  |  

Dahl, T.B., A. Yndestad, M. Skjelland, E. Oie and A. Dahl et al., 2007. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation, 115: 972-980.
CrossRef  |  Direct Link  |  

Dedoussis, G.V., A. Kapiri, A. Samara, D. Dimitriadis and D. Lambert et al., 2009. Visfatin: The link between inflammation and childhood obesity. Diabetes Care, 32: e71-e71.
CrossRef  |  Direct Link  |  

Dos Santos Costa, C., T.O. Hammes, F. Rohden, R. Margis and J.W. Bortolotto et al., 2010. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obesity Surg., 20: 633-639.
CrossRef  |  Direct Link  |  

Fukuhara, A., M. Matsuda, M. Nishizawa, K. Segawa and M. Tanaka et al., 2005. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science, 307: 426-430.
CrossRef  |  Direct Link  |  

Hsu, C.Y., P.H. Huang, T.H. Chen, C.H. Chiang and H.B. Leu et al., 2015. Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients. Am. J. Hypertens.,

Huang, Y., W. Li, L. Dong, R. Li and Y. Wu, 2013. Effect of statin therapy on the progression of common carotid artery intima-media thickness: An updated systematic review and meta-analysis of randomized controlled trials. J. Atheroscler. Thromb., 20: 108-121.
Direct Link  |  

Kadoglou, N.P., N. Sailer, A. Kapelouzou, S. Lampropoulos and I. Vitta et al., 2012. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol., 49: 269-276.
CrossRef  |  

Komatsu, J., M. Fujiwara, M. Matsuura, S. Ito and M. Oritsu, 2012. Study on the usefulness of High-Molecular-Weight (HMW)-adiponectin level check of Japanese general population upon health check: Comparison of carotid ultrasonography measurement. Clin. Biochem., 45: 72-76.
CrossRef  |  Direct Link  |  

Kong, Q., M. Xia, R. Liang, L. Li, X. Cu, Z. Sun and J. Hu, 2014. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med. J., 55: 383-387.
Direct Link  |  

Korou, L.M., G. Agrogiannis, A. Pantopoulou, I.S. Vlachos, D. Iliopoulos, T. Karatzas and D.N. Perrea, 2010. Comparative antilipidemic effect of N-acetylcysteine and sesame oil administration in diet-induced hypercholesterolemic mice. Lipids Health Dis., Vol. 9.

Kostapanos, M.S., C.S. Derdemezis, T.D. Filippatos, H.J. Milionis and D.N. Kiortsis et al., 2008. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur. J. Pharmacol., 578: 249-252.
CrossRef  |  

Larsson, P.T., S. Hallerstam, S. Rosfors and N.H. Wallen, 2005. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int. Angiology, 24: 43-51.
Direct Link  |  

Li, Y., T.R. Gilbert, A.H. Matsumoto and W. Shi, 2008. Effect of aging on fatty streak formation in a diet-induced mouse model of atherosclerosis. J. Vasc. Res., 45: 205-210.
CrossRef  |  

Liakos, C.I., E.A. Sanidas, D.N. Perrea, C.A. Grassos and V. Chantziara et al., 2015. Apelin and visfatin plasma levels in healthy individuals with high normal blood pressure. Am. J. Hypertens., 10.1093/ajh/hpv136

Petreanu, M., N. Eleuterio, A.A. Bosco and V.C. Sandrim, 2014. Effect of simvastatin treatment on plasma visfatin levels in obese women. Gynecol. Endocrinol., 30: 577-580.
CrossRef  |  

Pfutzner, A., M. Hanefeld, G. Lubben, M.M. Weber and E. Karagiannis et al., 2007. Visfatin: A putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk results from the PIOSTAT study. Horm. Metab. Res., 39: 764-768.
Direct Link  |  

Qiao, L. and J. Shao, 2006. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J. Biol. Chem., 281: 39915-39924.
CrossRef  |  

Shi, W., X. Wang, D.M. Shih, V.E. Laubach, M. Navab and A.J. Lusis, 2002. Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circ., 105: 2078-2082.
CrossRef  |  

Tian, L., N. Luo, R.L. Klein, B.H. Chung, W.T. Garvey and Y. Fu, 2009. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis, 202: 152-161.
CrossRef  |  

Tian, L., N. Luo, X. Zhu, B.H. Chung and W.T. Garvey et al., 2012. Adiponectin-adipoR1/2-APPL1 signaling axis suppresses human foam cell formation: Differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis, 221: 66-75.
CrossRef  |  

Tuttolomondo, A., D. Di Raimondo, R. Pecoraro, V. Arnao, A. Pinto and G. Licata, 2012. Atherosclerosis as an inflammatory disease. Curr. Pharm. Des., 18: 4266-4288.
Direct Link  |  

Wan, Q., X. Cui, J. Shao, F. Zhou and Y. Jia et al., 2014. Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice by upregulating visfatin expression. Cell Stress Chaperones, 19: 715-724.
CrossRef  |  

Wang, P., T.Y. Xu, Y.F. Guan, D.F. Su and G.R. Fan et al., 2009. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc. Res., 81: 370-380.
Direct Link  |  

Zhou, F., Y. Pan, Z. Huang, Y. Jia and X. Zhao et al., 2013. Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor: A and CD36. Cell Stress Chaperones, 18: 643-652.
CrossRef  |